Which peptides can you actually get in the EU, in injectable and non-injectable form?

The short answer

In the EU, the peptides you can legitimately get split into three tiers: prescription injectables approved by the EMA (the GLP-1s — Wegovy, Ozempic, Mounjaro, Saxenda), one prescription oral peptide (Rybelsus, oral semaglutide), and cosmetic topical peptides sold over the counter. Almost everything else the peptide community discusses — BPC-157, TB-500, the GH secretagogues — is unapproved and genuinely harder to obtain in the EU than in the US.

Evidence tier: 2 for the regulatory facts (EMA approvals are documented); the access/sourcing observations are practical and region-dependent. This is education, not medical or legal advice — rules and enforcement vary by member state.

The key points:

• Injectable, prescription, EMA-approved: the GLP-1 class (semaglutide, tirzepatide, liraglutide)
• Non-injectable, prescription: Rybelsus — oral semaglutide — the main approved oral peptide drug
• Non-injectable, over-the-counter: cosmetic topical peptides (copper peptides, argireline-type)
• Everything else is gray-market — and EU access is tighter than in the US

This builds on our GLP-1 complete guide; for the legal framing see our peptide legal status guide.

Why peptides are harder to get in the EU

Evidence tier: 2–3 — regulatory structure plus practical observation.

The EU isn't more permissive about research peptides than the US — in most respects it's tighter. Three structural reasons. First, the EU has no equivalent of the large US "research chemical" vendor ecosystem that ships domestically; EU buyers usually rely on imports, which face stricter customs scrutiny. Second, ingestible or injectable substances marketed for human-adjacent use can run into the EU's novel food rules and medicines law, which makes openly selling them within the bloc legally fraught. Third, prescription medicines (including the approved GLP-1s) require an actual prescription, and "telehealth → compounded peptide" routes common in the US are far less developed.

The net effect is the pattern the community notices: the approved, prescription peptides are obtainable through a doctor (subject to availability and cost), the cosmetic topicals are freely available, and the unapproved research peptides are both legally riskier and logistically harder to source than they are stateside. The rest of this guide maps what actually falls in each bucket.

What injectable peptides are available in the EU?

Evidence tier: 1–2 — EMA marketing authorizations.

The injectable peptides you can get legitimately in the EU are, overwhelmingly, the GLP-1 class, all by prescription. Semaglutide is authorized as Wegovy for weight management and Ozempic for type 2 diabetes (EMA: Wegovy). Tirzepatide is authorized as Mounjaro for both diabetes and weight management (EMA: Mounjaro). Older GLP-1s — liraglutide (Saxenda for weight, Victoza for diabetes), dulaglutide (Trulicity), and exenatide — are also EMA-approved and available. These are real, regulated medicines: prescribed, pharmacy-dispensed, and quality-controlled.

The main caveat isn't legality but supply and access: demand has driven EU-wide shortages of GLP-1s, and the EMA has had to coordinate actions to manage them (EMA on GLP-1 shortages). Beyond the GLP-1s, the injectable "community" peptides — BPC-157, TB-500, ipamorelin/CJC-1295, tesamorelin (Egrifta is US-approved, limited in the EU), PT-141 — are not EMA-approved for general use and are not legitimately available; they exist only via the gray market. So the honest injectable map is: GLP-1s yes (with a prescription and supply permitting), almost everything else no.

What non-injectable peptides can you actually get?

Evidence tier: 2 — approval status plus cosmetic-market reality.

The non-injectable options split cleanly into prescription and over-the-counter. The standout prescription oral peptide is Rybelsus — oral semaglutide — EMA-approved for type 2 diabetes. It's notable as essentially the only oral GLP-1 peptide drug available, with the practical quirk that oral peptide absorption is poor, so it must be taken on an empty stomach with a small sip of water and a wait before eating, and its weight effect is somewhat less than the injectable form. For the drug itself, see our semaglutide deep dive.

The over-the-counter non-injectable peptides are the cosmetic topicals: copper peptides (GHK-Cu) and signal peptides like the argireline family appear in serums and creams sold legally across the EU as cosmetics. They're low-risk and freely available — but they're regulated as cosmetics, meaning they're sold for skin appearance, not for the systemic effects sometimes claimed online. Other non-injectable routes the community asks about — nasal nootropic peptides like Semax and Selank — are not EU-approved (they're essentially Russia-specific), so despite being "non-injectable," they're as gray-market in the EU as the injectables.

Is it legal to buy research peptides in the EU?

Evidence tier: 2–3 — regulatory reasoning; not legal advice.

This is where people get into trouble, so it's worth being precise. The approved medicines (GLP-1s, Rybelsus) are legal with a prescription. Cosmetic topical peptides are legal to buy and use. But the unapproved research peptides occupy a grey zone: they're typically sold "for research use only, not for human consumption," which is the seller's attempt to sidestep medicines law. Buying them isn't necessarily a criminal act for an individual in every member state, but importing unapproved injectables can run into customs seizure, novel-food and medicines regulations, and — crucially — there's no consumer protection on quality because they're not regulated products.

A specific warning: Melanotan-II and similar are explicitly flagged by EU and national regulators as unlicensed and unsafe, and have been the subject of health warnings. The practical and honest position is that "research peptide" sourcing in the EU combines legal ambiguity, customs risk, and zero quality assurance — which is exactly why independent testing matters so much when people proceed anyway (see our safety and sourcing guide). This is general information, not legal advice, and the specifics genuinely vary by country.

So what should an EU-based person do?

Evidence tier: 3 — practical synthesis.

Match your goal to what's actually accessible. If the goal is weight or metabolic (the most common reason people look), the legitimate route is a prescription GLP-1 through a doctor — Wegovy/Mounjaro injectable or Rybelsus oral — subject to eligibility, cost, and the ongoing supply situation. If the goal is skin, the cosmetic topical peptides are freely and safely available over the counter. Those two buckets cover the large majority of mainstream peptide interest with regulated, quality-assured products.

If the interest is in the research peptides (BPC-157, the GH secretagogues, nasal nootropics), the honest guidance is that EU access is legally murky, logistically harder than in the US, and entirely without quality oversight — so the bar for proceeding should be high, the sourcing scrutiny higher, and the expectations about legality and customs realistic. Across all of it, a prescriber is the right partner for the approved options, and our tirzepatide and GLP-1 guides cover the medicines themselves in depth.

Cost, prescriptions, and the telehealth gap

Evidence tier: 2–3 — access/system observation, varies by country.

Even for the approved peptides, "available" and "easy to get" aren't the same thing in the EU, and the gap is mostly about the access system rather than legality. The GLP-1s require a genuine prescription, and whether you qualify, what it costs, and whether it's reimbursed vary enormously between member states and between diabetes and weight-management indications. In several countries the weight-management indication is largely private-pay, which makes the real-world barrier financial rather than regulatory. Layer the ongoing supply shortages on top, and even an eligible, prescribed patient can struggle to fill a script.

The structural contrast with the US is the telehealth-to-compounding pipeline. In the US, a large ecosystem of telehealth providers and compounding pharmacies grew up around GLP-1 demand, creating relatively frictionless (if variable-quality) access. The EU has nothing equivalent at scale: compounding rules are tighter, cross-border prescribing is constrained, and the "click, consult, ship" model is far less developed. That's a big part of why EU residents perceive peptides — even the approved ones — as harder to obtain: the legal product exists, but the convenient access rails that normalized it elsewhere largely don't.

For research peptides the access gap is even starker, and it compounds with the legal ambiguity discussed above. There's no domestic vendor scene to speak of, imports draw customs attention, and there's no compounding back-channel. The practical consequence is that EU residents who go looking for unapproved peptides face higher prices, slower and riskier shipping, and a greater chance of seizure or of receiving an untested product — all reasons the calculus tilts harder toward the regulated options where they exist, and toward serious sourcing scrutiny where someone proceeds anyway.

Limitations

This is educational content, not medical or legal advice.

• Rules and enforcement vary by EU member state — this is a general overview, not country-specific guidance.
• Approval status changes — EMA authorizations and indications are updated over time; verify current status.
• GLP-1 supply fluctuates — approved drugs can be hard to fill during shortages.
• "Research use only" labeling does not make a compound safe or clearly legal to use in humans.
• Unapproved peptides carry no quality assurance — verify any sourcing via Finnrick, and understand the legal risk.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

In the EU, legitimately available peptides come down to three tiers: prescription injectable GLP-1s (Wegovy, Ozempic, Mounjaro, Saxenda), one prescription oral peptide (Rybelsus, oral semaglutide), and over-the-counter cosmetic topicals (copper and signal peptides). Everything else the community discusses — BPC-157, TB-500, GH secretagogues, nasal nootropics like Semax/Selank — is unapproved, gray-market, and genuinely harder to source in the EU than in the US, with legal ambiguity and no quality oversight. Match your goal to the regulated option where one exists, and treat the rest with realistic caution.

Related on this site

• GLP-1 complete guide (2026)
• Peptide legal status guide (2026)
• Semaglutide deep dive (2026)
• Tirzepatide deep dive (2026)
• Peptide safety and sourcing: the practical guide
• Our evidence-tier framework

References

• European Medicines Agency. Wegovy (semaglutide) — EPAR / medicine overview. EMA: Wegovy — EU marketing authorization for weight management.
• European Medicines Agency. Mounjaro (tirzepatide) — EPAR / medicine overview. EMA: Mounjaro — EU authorization for diabetes and weight management.
• European Medicines Agency. EU actions to tackle shortages of GLP-1 receptor agonists. EMA news — access/supply context.
• Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 384(11):989-1002. PMID 33567185 — efficacy basis for the approved GLP-1s.